Rare diseases
Investigational molecules
Locations
161 Oyster Point Boulevard, 94080-2042, United States
Research activity includes early Alzheimer’s disease and other disorders affecting cognitive decline and brain function, with interest in central nervous system biomarkers and neuroprotective approaches.
The portfolio reflects a focus on therapies intended to address disease processes within the brain and support measurable neurological outcomes.
Denali Therapeutics Inc. runs clinical trials in conditions such as Mucopolysaccharidosis II, Glycogen storage disease type II, Frontotemporal dementia, Parkinson's disease, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DNL952 in Adults with Late‑Onset Pompe Disease
GermanyStudy on the Safety and Effects of DNL593 for Patients with Frontotemporal Dementia
BelgiumStudy on Long-Term Safety and Effects of DNL310 for Patients with Mucopolysaccharidosis Type II (MPS II)
BelgiumStudy on the Safety and Effects of BIIB122 for Patients with LRRK2-Associated Parkinson's Disease
GermanyStudy on the Effectiveness and Safety of DNL310 vs Idursulfase for Children and Young Adults with Mucopolysaccharidosis Type II
BelgiumStudy on the Safety of DNL310 for Children with Hunter Syndrome
The NetherlandsIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
